The 2022 annual report from EKOBOT is without information that can have a significant price impact and after the recent successful rights issue, it would
Biosergen: 1.5 million people die each year from fungal infections. Biosergen, which has FDA orphan drug status, is developing an antifungal drug that is more
CS Medica has entered into a joint venture and investment agreement with Chinese Inner Mongolia RongShi Hi-Tech Co. Ltd. regarding production of CS Medica’s CANNASEN
Ekobot: Ticker EKOBOT | Price: 3.49 SEK | Market Cap: 47 MSEK | YTD price development: -12% EKOBOT has developed and sells an agricultural robot
Nexcom experienced a 41% drop in revenue in 2022 to DKK 8M and a net loss of DKK 19M (DKK -21M in 2021). This year,
Biosergen: 1.5 million people die each year from fungal infections. Biosergen, which has FDA orphan drug status, is developing an antifungal drug that is more
After the 2022 annual report and extraordinary general meeting, Ekobot is ready for the partially underwritten rights issue, providing capital for delivery of orders received,
Mdundo’s H1 results (July – December 2022) showed continued high growth across all KPIs with 23.4 million active users, 500,000 music tracks on Mdundo’s own
Ekobot expects to sell 25 of its unique farming robots this year, sign a distribution agreement in the Danish market and get one pilot customer
Biosergen has received approval for the next step in its phase 1 study of its drug against deadly fungal infections, which has blockbuster potential. Not
Kapital Partner performs or has within the last 12 months performed corporate finance, market relations, investor relations, Certified Adviser or other advisory activities for the following listed companies: NORD.investments, Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.
Del indlægget på sociale media eller på email.